Marshall Wace LLP Purchases 8,203 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Marshall Wace LLP raised its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 44.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 26,800 shares of the biotechnology company’s stock after acquiring an additional 8,203 shares during the quarter. Marshall Wace LLP’s holdings in ADMA Biologics were worth $300,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Quest Partners LLC bought a new stake in ADMA Biologics during the 2nd quarter valued at $29,000. EntryPoint Capital LLC purchased a new position in ADMA Biologics during the 1st quarter worth $31,000. CWM LLC grew its stake in ADMA Biologics by 114.2% during the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock worth $92,000 after buying an additional 4,367 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in ADMA Biologics during the 2nd quarter worth about $93,000. Finally, Viewpoint Capital Management LLC lifted its position in ADMA Biologics by 18.6% during the 1st quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 2,416 shares during the period. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Price Performance

NASDAQ:ADMA opened at $17.15 on Friday. ADMA Biologics, Inc. has a 12 month low of $3.06 and a 12 month high of $21.13. The stock has a 50 day moving average of $17.61 and a two-hundred day moving average of $12.24. The company has a current ratio of 6.87, a quick ratio of 2.80 and a debt-to-equity ratio of 0.74. The firm has a market cap of $4.00 billion, a P/E ratio of 122.46 and a beta of 0.62.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. The business had revenue of $107.20 million during the quarter, compared to analyst estimates of $86.44 million. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The business’s revenue was up 78.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.02) earnings per share. On average, analysts expect that ADMA Biologics, Inc. will post 0.49 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Young Kwon sold 60,000 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total value of $1,095,600.00. Following the transaction, the director now directly owns 241,441 shares in the company, valued at approximately $4,408,712.66. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, Director Young Kwon sold 60,000 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total value of $1,095,600.00. Following the transaction, the director now directly owns 241,441 shares in the company, valued at approximately $4,408,712.66. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Lawrence P. Guiheen sold 9,000 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the transaction, the director now owns 153,941 shares in the company, valued at $2,843,290.27. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 466,900 shares of company stock worth $8,224,121 over the last ninety days. Corporate insiders own 3.70% of the company’s stock.

Wall Street Analysts Forecast Growth

ADMA has been the subject of a number of research reports. HC Wainwright lifted their price target on ADMA Biologics from $10.00 to $18.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Mizuho boosted their price objective on ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a report on Thursday, June 20th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $20.00 price objective on shares of ADMA Biologics in a report on Friday, September 20th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $15.50.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.